Answers are grounded in this paper and cite their sources.
Sarcopenia is a major contributor to frailty, disability and adverse clinical outcomes in older adults, yet its diagnosis remains challenging in routine practice, particularly in acutely unwell or immobile patients. Circulating biomarkers may provide an objective adjunct to current assessment strategies. Among these, brain-derived neurotrophic factor (BDNF) has attracted interest because of its role in neuromuscular function and muscle maintenance. This systematic review evaluates the association between BDNF and sarcopenia. A systematic search of MEDLINE and EMBASE was conducted up to July 2025 in accordance with PRISMA guidelines. Seven studies comprising 886 participants were included. Circulating BDNF levels demonstrated associations with key sarcopenia parameters, including muscle strength, physical performance and muscle mass. Diagnostic performance was moderate, with area under the curve values ranging from 0.70 to 0.76. However, the direction of association varied across populations, with both increased and decreased BDNF levels reported in sarcopenic individuals, likely reflecting differences in disease context, metabolic status and methodological approaches. Overall, BDNF appears to be a biologically plausible biomarker reflecting neuromuscular integrity, but is unlikely to function as a standalone diagnostic tool. It may have clinical utility as part of a multi-biomarker approach to sarcopenia assessment, particularly in settings where functional testing is limited.
No takes yet. Share an insight, caveat, or question.
Wielińska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: